Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 11/20 | 0.42 |
| ▸ | PRP4K | Q13523 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330764 | 0.88 | DYRK1A (0.39) | ERCC5FEN1DYRK1ADYRK1BPRP4K | |
| SCHEMBL29831759 | 0.88 | DYRK1A (0.39) | ERCC5FEN1DYRK1ADYRK1BPRP4K | |
| SCHEMBL23300749 | 0.86 | ERCC5 (0.39) | ERCC5FEN1DYRK1ADYRK1BPRP4K | |
| SCHEMBL23331122 | 0.83 | ERCC5 (0.46) | ERCC5FEN1DYRK1ADYRK1BHPGD | |
| SCHEMBL29831644 | 0.83 | STING1 (0.38) | ERCC5FEN1DYRK1ADYRK1BPRP4K | |
| SCHEMBL23330740 | 0.83 | STING1 (0.38) | ERCC5FEN1DYRK1ADYRK1BPRP4K | |
| SCHEMBL29943542 | 0.78 | ADRA2A (0.37) | ERCC5FEN1ADRA2AADRA2B | |
| SCHEMBL23331104 | 0.78 | ADRA2A (0.37) | ERCC5FEN1ADRA2AADRA2B | |
| SCHEMBL23300721 | 0.71 | CYP1A2 (0.45) | ERCC5FEN1DYRK1ADYRK1BHPGD | |
| SCHEMBL29831159 | 0.69 | ADRA2A (0.34) | DYRK1ADYRK1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | ERCC5 587/4885FEN1 694/4885DYRK1A 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.